drugset / Trial / NCT00903838
A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.
Timeline
- Start
- 2009-09
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pardoprunox | Small molecule | 1.5 mg | — |
| Subject | Pardoprunox | Small molecule | 12 mg | — |
| Comparator | Pramipexole | Unknown | 0.75 mg | — |
| Comparator | Pramipexole | Unknown | 4.5 mg | — |